No evidence to show increased risk of incident hypertension w/ TNFi use, after accounting for baseline & time-dependent confounding factors, in prospective AS cohort. Abs 0910 #ACR21 #RheumNow @RheumNow https://t.co/1SpQ51ftlK

• The Association of TNF Inhibitor Use with Incident Hypertension in Ankylosing S…

French, real-world axSpA cohort analysis shows SEC and TNFi retention rates similar. What do you see in your practice? Abs 0911 #ACR21 #RheumNow @RheumNow https://t.co/vu3zUwfktl https://t.co/v6DLjWJMn4

• Drug Retention of Tumor Necrosis Factors and IL-17 Inhibitors in Axial Spondylo…

@rheum_cat presenting a really well designed study looking at association between TNFi use and incident hypertension in axSpA. No association found. Abstr#0910 #ACR21 @RheumNow https://t.co/w7o1oDreVL

And here is ORAL-Surveillance, small increase in MACE and malignancy with tofacitinib vs TNFi. 1 extra MACE per 319-567 patient years, 1 extra malignancy per 275 patient years. Abstr#0831 #ACR21 @RheumNow https://t.co/wMJnspTTBy

Drug retention of TNFi vs. secukinumab in AxSpA pts Abs#911 ⭐️46% discontinued either treatment ⭐️TNFi with slightly better drug retention ⭐️Age, BASDAI, BMI did not favor any group ⭐️inefficacy - main reason #ACR21 @RheumNow https://t.co/ynoomYrTvX

So it's day 2 at #ACR21, and you know what that means - it's ORAL Surveillance day! This is the figure everyone will be talking about, leading up to details in the plenary. Why are the other bars higher than the pink bars? ABST0831 plenty of @RheumNow coverage coming on this https://t.co/B80cSmhNV7

ORAL Surveillance In mod-severe RA pts >50yo, with CV RF & no hx malignancy, patient-years of exposure required for one event (vs TNFi): MACE tofa 5mg bid: 567 tofa 10mg bid: 319 malignancy tofa 5mg bid: 276 tofa 10mg bid: 275 #ACR21 ABST0831 @RheumNow https://t.co/9vyXPTMFzj

• Safety and Efficacy of Tofacitinib vs TNF Inhibitors in RA Patients Aged 50 Yea…